ADC Therapeutics SA (ADCT)
4.775
+0.32
(+7.30%)
USD |
NYSE |
May 07, 13:36
ADC Therapeutics Cash from Investing (Quarterly): -0.527M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.527M |
| September 30, 2023 | -0.661M |
| June 30, 2023 | -1.012M |
| March 31, 2023 | -1.016M |
| December 31, 2022 | 1.704M |
| September 30, 2022 | -0.254M |
| June 30, 2022 | -0.689M |
| March 31, 2022 | -1.448M |
| Date | Value |
|---|---|
| December 31, 2021 | -0.83M |
| September 30, 2021 | -2.338M |
| June 30, 2021 | -2.848M |
| March 31, 2021 | -0.657M |
| December 31, 2020 | -0.793M |
| September 30, 2020 | -1.401M |
| June 30, 2020 | -0.138M |
| March 31, 2020 | -0.496M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-2.848M
Minimum
Jun 2021
1.704M
Maximum
Dec 2022
-0.8377M
Average
-0.741M
Median
Cash from Investing (Quarterly) Benchmarks
| Roche Holding AG | -- |
| Novartis AG | -899.00M |
| AC Immune SA | 25.14M |
| CRISPR Therapeutics AG | -81.45M |
| Addex Therapeutics Ltd | -0.0012M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -33.07M |
| Cash from Financing (Quarterly) | 1.639M |
| Free Cash Flow | -121.90M |
| Free Cash Flow Per Share (Quarterly) | -0.4058 |
| Free Cash Flow to Equity (Quarterly) | -34.09M |
| Free Cash Flow to Firm (Quarterly) | -23.09M |
| Free Cash Flow Yield | -31.24% |